Prediction, by retinal location, of the onset of diabetic edema in patients with nonproliferative diabetic retinopathy

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 9, 2011, Pages 6825-6831

  Harrison, Wendy W ^a   Bearse, Marcus A Jr ^a   Schneck, Marilyn E ^a   Wolff, Brian E ^a   Jewell, Nicholas P ^b   Barez, Shirin ^a   Mick, Andrew B ^c   Dolan, Bernard J ^c   Adams, Anthony J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; GLYCOSYLATED HEMOGLOBIN;

ADULT; AGE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; ELECTRORETINOGRAPHY; FEMALE; HUMAN; MALE; NONBIOLOGICAL MODEL; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETINA FLUORESCEIN ANGIOGRAPHY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEX; SYSTOLIC BLOOD PRESSURE; AGED; BLOOD; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; EYE FUNDUS; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; METABOLISM; METHODOLOGY; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; ONSET AGE; OPTICAL COHERENCE TOMOGRAPHY; PAPILLEDEMA; PATHOLOGY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; RETINA; RISK FACTOR; UNITED STATES;

ADULT; AGE OF ONSET; AGED; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; ELECTRORETINOGRAPHY; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; FUNDUS OCULI; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; PAPILLEDEMA; PREDICTIVE VALUE OF TESTS; RETINA; RISK ASSESSMENT; RISK FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; UNITED STATES; YOUNG ADULT;

EID: 80055077496     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.11-7533     Document Type: Article

References (49)

1. Complications of diabetes in the United States. American Diabetes Association. 2009. May be accessed at http://www.diabetes.org
2. Girach A, Lund-Andersen H. Diabetic macular oedema: a clinical overview. Int J Clin Pract. 2007;61:88-97.
3. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology. 1995;102:7-16.
4. Goebel W, Kretzchmar-Gross T. Retinal thickness in diabetic retinopathy: a study using optical coherence tomography (OCT). Retina. 2002;22:759-767.
5. Chew EY, Ferris FL 3rd, Csaky KG, et al. The long-term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow-up study. Ophthalmology. 2003;110:1683-1689.
6. Nicholson BP, Schachat AP. A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2010;248:915-930.
7. Tsilimbaris M. Intravitreal combination of triamcinolone acetonide and bevacizumab (Kenacort-Avastin) in diffuse diabetic macular edema. Semin Ophthalmol. 2009;24:225-230.
8. Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010; 117:1064-1077.
9. Emanuele N, Moritz T, Klein R, et al. Ethnicity, race, and clinically significant macular edema in the Veterans Affairs Diabetes Trial (VADT). Diabetes Res Clin Pract. 2009;86:104-110.
10. Lopes de Faria J, Jalkh AE, Trempe CL, McMeel JW. Diabetic macular edema: risk factors and concomitants. Acta Ophthalmol Scand. 1999;77:170-175.
11. Karacorlu M, Ozdemir H, Senturk F, Arf Karacorlu S, Uysal O. Macular function by multifocal electroretinogram in diabetic macular edema after intravitreal triamcinolone acetonide injection. Eur J Ophthalmol. 2008;18:601-608.
12. Leozappa M, Micelli Ferrari T, Grossi T, et al. Prognostic prediction ability of postoperative multifocal ERG after vitrectomy for diabetic macular edema. Eur J Ophthalmol. 2008;18:609-613.
13. Fortune B, Schneck ME, Adams AJ. Multifocal electroretinogram delays reveal local retinal dysfunction in early diabetic retinopathy. Invest Ophthalmol Vis Sci. 1999;40:2638-2651.
14. Palmowski AM, Sutter EE, Bearse MA Jr, Fung W. Mapping of retinal function in diabetic retinopathy using the multifocal electroretinogram. Invest Ophthalmol Vis Sci. 1997;38:2586-2596.
15. Greenstein VC, Holopigian K, Hood DC, Seiple W, Carr RE. The nature and extent of retinal dysfunction associated with diabetic macular edema. Invest Ophthalmol Vis Sci. 2000;41:3643-3654.
16. Holm K, Larsson J, Lövestam-Adrian M. In diabetic retinopathy, foveal thickness of 300 μm seems to correlate with functionally significant loss of vision. Doc Ophthalmol. 2007;114:117-124.
17. Lövestam-Adrian M, Holm K. Multifocal electroretinography amplitudes increase after photocoagulation in areas with increased retinal thickness and hard exudates. Acta Ophthalmologica. 2010; 88:188-192.
18. Han Y, Schneck ME, Bearse MA Jr, et al. Formulation and evaluation of a predictive model to identify the sites of future diabetic retinopathy. Invest Ophthalmol Vis Sci. 2004;45:4106-4112.
19. Han Y, Bearse MA Jr, Schneck ME, Barez S, Jacobsen CH, Adams AJ. Multifocal electroretinogram delays predict sites of subsequent diabetic retinopathy. Invest Ophthalmol Vis Sci. 2004;45:948-954.
20. Ng JS, Bearse MA Jr, Schneck ME, Barez S, Adams AJ. Local diabetic retinopathy prediction by multifocal ERG delays over 3 years. Invest Ophthalmol Vis Sci. 2008;49:1622-1628.
21. Bearse MA Jr, Adams AJ, Han Y, et al. A multifocal electroretinogram model predicting the development of diabetic retinopathy. Prog Retin Eye Res. 2006;25:425-448.
22. Harrison WW, Bearse MA Jr, Ng JS, et al. Multifocal electroretinograms predict onset of diabetic retinopathy in adult patients with diabetes. Invest Ophthalmol Vis Sci. 2011;52:772-777.
23. Hood D, Li J. A technique for measuring individual multifocal ERG records. In: Yager D, ed. Non-invasive Assessment of the Visual System. Trends in Optics and Photonics. Washington, DC: Optical Society of America; 1997:33-41.
24. Jewell NP. Statistics for Epidemiology. Boca Raton, FL: Chapman & Hall, 2004.
25. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics. 1988;44: 1049-1060.
26. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982; 143:29-36.
27. Burman P. A comparative study of ordinary cross-validation, v-fold cross-validation and the repeated learning-testing methods. Biometrika. 1989;76:503-514.
28. Kohavi R. A study of cross-validation and bootstrap for accuracy estimation and model selection. In: Proceedings of the Fourteenth International Joint Conference on Artificial Intelligence (IJCAI). Vol. 1. Chicago: IJCAI; 1995:1137-1143.
29. Holm K, Ponjavic V, Lövestam-Adrian M. Using multifocal electroretinography hard exudates affect macular function in eyes with diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2010; 248:1241-1247.
30. Xu J, Hu G, Huang T, Huang H, Chen B. Using multifocal ERG responses to discriminate diabetic retinopathy. Doc Ophthalmol. 2006;112:201-207.
31. Harrison WW, Bearse MA Jr, Ng JS, Barez S, Schneck ME, Adams AJ. Reproducibility of the mfERG between instruments. Doc Ophthalmol. 2009;119:67-78.
32. Beulens JW, Patel A, Vingerling JR, et al. Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial. Diabetologia. 2009;52: 2027-2036.
33. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317:703-713.
34. Manaviat MR, Rashidi M, Afkhami-Ardekani M. Four years incidence of diabetic retinopathy and effective factors on its progression in type II diabetes. Eur J Ophthalmol. 2008;18:572-577.
35. Chase HP, Garg SK, Jackson WE, et al. Blood pressure and retinopathy in type I diabetes. Ophthalmology. 1990;97:155-159.
36. Klein BE, Klein R, Moss SE, Palta M. A cohort study of the relationship of diabetic retinopathy to blood pressure. Arch Ophthalmol. 1995;113:601-606.
37. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology. 2009;116:497-503.
38. Ozawa G, Bearse MA, Bronson-Castain KW, et al. Retinal function differs between male and female subjects with type 2 diabetes and no retinopathy [E-Abstract]. Optom Vis Sci. 2010;97:100952.
39. Zhang X, Saaddine JB, Chou C-F, et al. Prevalence of diabetic retinopathy in the United States, 2005-2008. JAMA. 2010;304: 649-656.
40. Varma R, Macias GL, Torres M, Klein R, Pena FY, Azen SP. Biologic risk factors associated with diabetic retinopathy: the Los Angeles Latino Eye Study. Ophthalmology. 2007;114:1332-1340.
41. Kohner EM, Aldington SJ, Stratton IM, et al. United Kingdom Prospective Diabetes Study, 30: diabetic retinopathy at diagnosis of non-insulin-dependent diabetes mellitus and associated risk factors. Arch Ophthalmol. 1998;116:297-303.
42. Pradeepa R, Anitha B, Mohan V, Ganesan A, Rema M. Risk factors for diabetic retinopathy in a South Indian type 2 diabetic population: the Chennai Urban Rural Epidemiology Study (CURES) Eye Study 4. Diabet Med. 2008;25:536-542.
43. Hirai FE, Knudtson MD, Klein BE, Klein R. Clinically significant macular edema and survival in type 1 and type 2 diabetes. Am J Ophthalmol. 2008;145:700-706.
44. Grauslund J, Green A, Kawasaki R, Hodgson L, Sjolie AK, Wong TY. Retinal vascular fractals and microvascular and macrovascular complications in type 1 diabetes. Ophthalmology. 2010;117: 1400-1405.
45. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology. 1984;91:1464-1474.
46. Klein R, Moss SE, Klein BE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. XI. The incidence of macular edema. Ophthalmology. 1989;96:1501-1510.
47. Gangnon RE, Davis MD, Hubbard LD, et al. A severity scale for diabetic macular edema developed from ETDRS data. Invest Ophthalmol Vis Sci. 2008;49:5041-5047.
48. Hudson C, Flanagan JG, Turner GS, Chen HC, Rawji MH, McLeod D. Exaggerated relative nasal-temporal asymmetry of macular capillary blood flow in patients with clinically significant diabetic macular oedema. Br J Ophthalmol. 2005;89:142-146.
49. Stratton IM, Kohner EM, Aldington SJ, et al. UKPDS 50: risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis. Diabetologia. 2001;44:156-163.